Follow Us
- Uganda’s Museveni wins 6th term, calls for peace after winning polls
- Thousands protest COVID restrictions in Vienna
- Washington : Armed man arrested at security checkpoint near US Capitol
- Taliban militants kill 12 pro-government Afghan militiamen
- Cameroon: Authorities urged to seek justice for recent deadly attacks
Johnson & Johnson COVID-19 Vaccine Produces Strong Immune Response in Phase 3 Clinical Trial
The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.
Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.
Johnson & Johnson has continued the scaling up of its manufacturing capacity and remains on track to meet its goal of providing one billion doses of a vaccine each year. The Company is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use and anticipates the first batches of a COVID-19 vaccine to be available for emergency use authorization in early 2021, if proven to be safe and effective.
Johnson & Johnson will develop and test its COVID-19 vaccine candidate in accordance with high ethical standards and sound scientific principles. The Company is committed to transparency and sharing information related to the Phase 3 ENSEMBLE study – including the study protocol.
“As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same – leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson. “As the world’s largest healthcare company, we are bringing to bear our best scientific minds, and rigorous standards of safety, in collaboration with regulators, to accelerate the fight against this pandemic. This pivotal milestone demonstrates our focused efforts toward a COVID-19 vaccine that are built on collaboration and deep commitment to a robust scientific process. We are committed to clinical trial transparency and to sharing information related to our study, including details of our study protocol.”
“We remain fully focused on developing an urgently needed, safe and effective COVID-19 vaccine for people around the world,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “We greatly value the collaboration and support from our scientific partners and global health authorities as our global team of experts work tirelessly on the development of the vaccine and scaling up our production capacity with a goal to deliver a vaccine for emergency use authorization in early 2021.”
The Janssen COVID-19 vaccine candidate leverages the Company’s AdVac® technology platform, which was also used to develop and manufacture Janssen’s European Commission approved Ebola vaccine and construct its Zika, RSV, and HIV vaccine candidates. Janssen’s AdVac® technology platform has been used to vaccinate more than 100,000 people to date across Janssen’s investigational vaccine programs.
With Janssen’s AdVac® technology, the vaccine, if successful, is estimated at launch to remain stable for two years at -20 °C and at least three months at 2-8° C. This makes the vaccine candidate compatible with standard vaccine distribution channels and would not require new infrastructure to get it to the people who need it.
PHASE 3 ENSEMBLE STUDY
Built on a legacy of purpose-driven actions and a commitment to diversity and inclusion, the Company aims to achieve representation of populations that have been disproportionately impacted by the pandemic in the implementation of its COVID-19 Phase 3 trial program. In the U.S., this includes significant representation of Black, Hispanic/Latinx, American Indian and Alaskan Native participants.
ENSEMBLE is being initiated in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) under Other Transaction Agreement HHSO100201700018C, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS.
In parallel, the Company has also agreed in principle to collaborate with the United Kingdom of Great Britain and Northern Ireland (the UK Government) on a separate Phase 3 clinical trial in multiple countries to explore a two-dose regimen of Janssen’s vaccine candidate.
“With our vaccine candidate now in our global Phase 3 trial, we are one step closer to finding a solution for COVID-19. We used a highly scientific and evidence-based approach to select this vaccine candidate. We are extremely grateful for the tireless efforts of our researchers and for the vital contributions of those participants who have volunteered to take part in our studies. Together, we are working to help combat this pandemic,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC, Johnson & Johnson.
The Company is in ongoing discussions with many stakeholders, including national governments and global organizations, as part of its efforts to meet its commitment to make the vaccine candidate accessible globally, provided the vaccine is demonstrated to be safe and effective and following regulatory approval.
Uganda’s Museveni wins 6th term, calls for peace after winning polls
Thousands protest COVID restrictions in Vienna
Indonesia earthquake death toll reaches to 56
First Person Cheese proves key to survival for Syrian refugee family amid pandemic
Guterres welcomes Palestinian announcement of elections as ‘crucial step’ towards unity
-
Paytm Money opens Stockbroking for all, targeting 10 lakh investors this fiscal -
High Bid Premium Effects : Big Corporate bleeds Odisha of Rs.1964 crs -
Farmers set fire tractor near India Gate to protest farm bills -
Canada Coronavirus cases reached 153,125 -
UN reform is ‘the need of the hour’: PM Modi -
Kaniha : JITPL Derang Plant runs with goons, agents and unscrupulous officials -
Johnson & Johnson COVID-19 Vaccine Produces Strong Immune Response in Phase 3 Clinical Trial -
Indian troops will fire If Chinese PLA attempts to overrun our troops : Official -
Pandemic shocks world, reinforces need for multilateralism, says Estonian President -
Terrorist attack on CRPF party in Budgam, CRPF jawan martyred, terrorist absconding -
Surat: Fire breaks out in ONGC plant, 3 people missing -
US : Tik Tok files petition for injunction in court -
NIgeria : 30 killed in fuel tanker explosion -
India lodges strong protest over Turkey's President's remarks on Kashmir -
Angul Coronavirus Update : Shopkeepers,vendors to be tested to detect COVID-19


-
Thousands protest COVID restrictions in ViennaRussia registers 27,250 new Covid-19 cases, 549 deaths, 24,447 recoveries in past 24 hours - HQBritain reports record number of new COVID-19 infectionsLegion of Merit Award from US recognises increasing consensus on Indo- US Strategic Partnership,says PM Modi
-
Woman lured for job, gangraped in Prayagraj, accused arrestedVice President of India urges Finance Commission and local bodies to encourage green BuildingsUS Electoral College vote makes Biden's White House win official7th Instalment of Rs.6,000 crore released to the States as back to back loan to meet the GST compensation shortfall